OncoDNA

OncoDNA is a biotechnology company specializing in precision medicine for the treatment of cancer. Founded in 2013, the company is headquartered in Gosselies, Belgium. OncoDNA uses advanced genomic and molecular analysis to provide oncologists and their patients with targeted therapeutic options based on the genetic makeup of individual cancers.

Overview[edit | edit source]

OncoDNA combines high-throughput next-generation sequencing (NGS), immunohistochemistry, and various molecular tests to analyze the DNA and RNA of cancer cells. This comprehensive approach allows for the identification of mutations, gene expressions, and other biomarkers that can influence a patient's response to certain cancer treatments. By understanding the specific characteristics of a cancer, OncoDNA aims to facilitate personalized treatment plans that can improve outcomes and reduce unnecessary side effects.

Services[edit | edit source]

The company offers a range of services to support oncologists in their clinical practice, including:

OncoDEEP: A molecular diagnostic test that screens solid tumors for a wide array of biomarkers and mutations. This service helps in identifying actionable targets for therapy.
OncoSTRAT&GO: An advanced test that combines the analysis of solid and liquid biopsies to provide a comprehensive view of a tumor's genetic landscape and potential resistance mechanisms.
OncoSELECT: A service focused on identifying specific mutations in cancer cells that can be targeted by available treatments.
OncoTRACE: A liquid biopsy test designed to monitor treatment response and detect minimal residual disease or early signs of relapse.

Research and Development[edit | edit source]

OncoDNA is actively involved in research and development to improve cancer diagnostics and treatment. The company collaborates with academic institutions, healthcare providers, and pharmaceutical companies worldwide to advance the field of precision oncology. Through these collaborations, OncoDNA contributes to the development of new biomarkers, therapeutic targets, and innovative diagnostic technologies.

Impact[edit | edit source]

The work of OncoDNA has the potential to significantly impact the field of oncology by enabling more personalized and effective treatment strategies. By tailoring therapy to the individual characteristics of each patient's cancer, precision medicine aims to improve survival rates, reduce the incidence of adverse reactions, and enhance the quality of life for cancer patients.

Challenges and Future Directions[edit | edit source]

Despite the promising advances in precision medicine, there are challenges to its widespread implementation, including the cost of genomic testing, the need for robust bioinformatics support, and the integration of molecular diagnostics into clinical practice. OncoDNA continues to work on addressing these challenges by developing more cost-effective testing methods, enhancing data analysis capabilities, and fostering partnerships that support the adoption of precision oncology.